SOHO 2020 | Impact of COVID-19 on CAR T-cell therapies

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the impact of the COVID-19 pandemic on the treatment and management of patients with hematological malignancies treated with CAR T-cell therapies, which are widely recognized as high-risk interventions. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).